- Investing Ideas
- Brazilian Pharmaceuticals & Biotech Potentially Undervalued Companies
Brazilian Pharmaceuticals & Biotech Potentially Undervalued Companies
Results
21
Companies with a Value score of at least 3, ordered by Value score
21 companies
Hypera
Market Cap: R$14.9b
Operates as a pharmaceutical company in Brazil.
HYPE3
R$21.17
7D
-1.6%
1Y
-10.9%
Novo Nordisk
Market Cap: R$1.3t
Engages in the research and development, manufacture, and distribution of pharmaceutical products.
N1VO34
R$30.69
7D
3.9%
1Y
-20.5%
Zoetis
Market Cap: R$32.1b
Engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health solutions for the animal health industry in the United States and internationally.
Z1TS34
R$25.12
7D
3.0%
1Y
-53.3%
Ouro Fino Saúde Animal Participações
Market Cap: R$1.4b
Engages in the development, production, and sale of veterinary drugs, vaccines, and other products for production and companion animals primarily in Brazil.
OFSA3
R$25.35
7D
0.8%
1Y
14.1%
Regeneron Pharmaceuticals
Market Cap: R$83.3b
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide.
REGN34
R$71.58
7D
4.1%
1Y
29.6%
United Therapeutics
Market Cap: R$22.0b
Engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally.
U2TH34
R$129.50
7D
0%
1Y
53.0%
Perrigo
Market Cap: R$2.0b
Provides over-the-counter health and wellness solutions in the United States, Europe, and internationally.
P1RG34
R$50.71
7D
-2.0%
1Y
-59.8%
Takeda Pharmaceutical
Market Cap: R$9.2t
Engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products.
TAKP34
R$92.25
7D
0%
1Y
9.4%
Exelixis
Market Cap: R$13.4b
An oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States.
E2XE34
R$137.40
7D
4.1%
1Y
29.5%
Ascendis Pharma
Market Cap: R$16.6b
Operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally.
A1SN34
R$85.00
7D
0%
1Y
19.4%
Sarepta Therapeutics
Market Cap: R$2.0b
A commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, siRNA platform, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases.
S1RP34
R$4.94
7D
3.6%
1Y
-9.0%
Neurocrine Biosciences
Market Cap: R$15.5b
Neurocrine Biosciences, Inc. discovers, develops, and commercialize pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders in the United States and internationally.
N1BI34
R$39.72
7D
-7.5%
1Y
7.6%
BioMarin Pharmaceutical
Market Cap: R$12.9b
A biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally.
B1MR34
R$171.19
7D
0.5%
1Y
9.2%
GSK
Market Cap: R$76.9b
Engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally.
G1SK34
R$53.80
7D
3.5%
1Y
23.2%
Bristol-Myers Squibb
Market Cap: R$136.9b
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide.
BMYB34
R$346.00
7D
3.0%
1Y
32.3%
Gilead Sciences
Market Cap: R$181.2b
A biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally.
GILD34
R$62.65
7D
4.5%
1Y
20.1%
Jazz Pharmaceuticals
Market Cap: R$16.5b
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally.
J2AZ34
R$88.02
7D
3.3%
1Y
n/a
Novartis
Market Cap: R$242.2b
Researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally.
N1VS34
R$78.40
7D
-0.3%
1Y
12.9%
Ultragenyx Pharmaceutical
Market Cap: R$2.5b
A biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Europe, the Middle East, Africa, and the Asia-Pacific.
R2AR34
R$13.46
7D
4.6%
1Y
-9.5%
CRISPR Therapeutics
Market Cap: R$5.8b
A gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform.
C2RS34
R$39.39
7D
13.7%
1Y
7.4%
AstraZeneca
Market Cap: R$189.8b
A biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines.
A1ZN34
R$142.37
7D
4.5%
1Y
-2.9%